JP2024514101A5 - - Google Patents
Info
- Publication number
- JP2024514101A5 JP2024514101A5 JP2023560806A JP2023560806A JP2024514101A5 JP 2024514101 A5 JP2024514101 A5 JP 2024514101A5 JP 2023560806 A JP2023560806 A JP 2023560806A JP 2023560806 A JP2023560806 A JP 2023560806A JP 2024514101 A5 JP2024514101 A5 JP 2024514101A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- chimeric antigen
- antigen receptor
- cells
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163169575P | 2021-04-01 | 2021-04-01 | |
| US63/169,575 | 2021-04-01 | ||
| PCT/US2022/023112 WO2022212879A1 (en) | 2021-04-01 | 2022-04-01 | Il-13ra2 chimeric antigen receptors and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514101A JP2024514101A (ja) | 2024-03-28 |
| JP2024514101A5 true JP2024514101A5 (enExample) | 2025-04-08 |
Family
ID=81384926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560806A Pending JP2024514101A (ja) | 2021-04-01 | 2022-04-01 | Il-13ra2キメラ抗原受容体および使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240189351A1 (enExample) |
| EP (1) | EP4314069A1 (enExample) |
| JP (1) | JP2024514101A (enExample) |
| WO (1) | WO2022212879A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4588939A1 (en) * | 2024-01-16 | 2025-07-23 | Universitat de Barcelona | Interleukin-13 receptor subunit alpha-2 (il13ralpha2) targeting moieties for the treatment and prevention of il13ralpha2-positive cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107683289B (zh) * | 2015-01-26 | 2021-08-06 | 芝加哥大学 | IL13Rα2结合剂和其在癌症治疗中的用途 |
| CN108456250B (zh) * | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| CN118374493A (zh) | 2017-05-17 | 2024-07-23 | 西雅图儿童医院(Dba西雅图儿童研究所) | 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法 |
| EP3765041A4 (en) * | 2018-03-14 | 2021-12-22 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | IL-13 CHIMERIC RECEPTOR ALPHA 2 (IL13RA2) ANTIGEN RECEPTOR FOR T-CELL T-CELL IMMUNOTHERAPY |
| WO2020210665A1 (en) * | 2019-04-12 | 2020-10-15 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with cd20 safety switch |
-
2022
- 2022-04-01 WO PCT/US2022/023112 patent/WO2022212879A1/en not_active Ceased
- 2022-04-01 EP EP22718479.3A patent/EP4314069A1/en active Pending
- 2022-04-01 JP JP2023560806A patent/JP2024514101A/ja active Pending
- 2022-04-01 US US18/285,218 patent/US20240189351A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI883026B (zh) | 抗dll3嵌合抗原受體及其用途 | |
| JP2023162180A (ja) | ヒト化抗muc1*抗体 | |
| JP2021510710A5 (enExample) | ||
| CN112639102A (zh) | 抗间皮素嵌合抗原受体(car)构建体及其用途 | |
| JP2019524693A5 (enExample) | ||
| JP2024023228A5 (enExample) | ||
| JP2019513370A5 (enExample) | ||
| JP2015513920A5 (enExample) | ||
| JP2018523493A5 (enExample) | ||
| JP2023550998A5 (enExample) | ||
| EP3405494A1 (en) | Ror2 antibody compositions and related methods | |
| CN108138172B (zh) | 抗体 | |
| JP7496965B2 (ja) | Bcmaに特異的な抗体およびキメラ抗原受容体 | |
| JP2022535410A5 (enExample) | ||
| JP2022525318A5 (enExample) | ||
| IL316226A (en) | Anti-ror1 antibody and ror1-targeting engineered cells | |
| AU2022353119A1 (en) | Composition of recombinant antigen binding molecules and method of making and using thereof | |
| JP2024105603A (ja) | CARライブラリおよびscFvの製造方法 | |
| JP2024514101A5 (enExample) | ||
| Pfeifer Serrahima et al. | Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies | |
| CA3174678A1 (en) | Compositions and methods for treatment of cancer | |
| CN114007626A (zh) | 用于治疗癌症的组合物和方法 | |
| WO2024037628A1 (zh) | 一种双特异性抗体及其应用 | |
| JP2024539079A5 (enExample) | ||
| JP2023549441A5 (enExample) |